Following the investment in acquiring NIPD Genetics, Medicover has been recently awarded Invest Cyprus International Investment Awards, a prize honoring international investors, individuals and companies in recognition of their significant contribution to the Cyprus economy. The prestigious award has reached its 10th edition this year and it has been targeting organizations that have invested directly in Cyprus and created added value for the local economy.
The award ceremony was held in Parklane Hotel in Limassol, under the auspices of the President of the Republic of Cyprus, Mr. Nicos Anastasiades and attended by political figures, industry leaders, investors and professionals from the services sector. Staffan Ternström has been presented the award and expressed his gratitude in front of the distinguished audience.
“This is a special recognition, and we are proud and honored to receive it. That is because our investment will be yielding for years to come, and I am not referring to a financial gain, but a meaningful impact to potentially millions of people around the world. We chose to invest in NIPD Genetics, a leading innovative biotechnology company whose advanced genetic testing services have tremendous potential. The investment strengthens Medicover's position in the genetic market and provides a solid foundation for further development with advanced diagnostic products and solutions. We see this prestigious award as further motivation to carry out our mission: to improve and sustain health and wellbeing.”, said Staffan Ternström, COO Medicover, Diagnostic Services.
Medicover has signed a strategic partnership with NIPD Genetics in 2018 investing in the company’s research and development capabilities for new tests. The acquisition of NIPD Genetics was completed in January 2022, placing Medicover in a new growth chapter, and supporting the vision of becoming a market leader in genetic testing.